Hoth Therapeutics Announces Approval from HREC in Australia for Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis


NEW YORK, June 21, 2022 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-centric company biopharmaceutical company, announced today has received approval from the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the next phase of its BioLexa trial for patients with atopic dermatitis.

Obtaining clearance is a critical step in our clinical trial in Australia. Hoth’s scientific advisors believe that Hoth’s atopic dermatitis solution, BioLexa, represents a significant global opportunity and look forward to advancing treatment through the clinic.

BioLexa is a patented and proprietary topical antimicrobial formulation under development for the treatment of staphylococcal biofilm-mediated diseases. Bacterial biofilms are specialized communities composed of bacteria adhering to a surface (biological and abiotic surfaces) and other bacteria, and often with a protective extracellular matrix. Mature bacterial biofilms often lead to chronic and recurrent infections that are difficult to treat due to the biofilm’s barrier effect that facilitates antibiotic resistance and evades immune system mechanisms. The BioLexa formulation is optimized to prevent the formation of staphylococcal biofilm, maintaining the bacteria in a state more susceptible to antimicrobial therapy. This novel mechanism of action has the potential to broadly treat clinical manifestations resulting from staphylococcal biofilm formation.

About Hoth Therapeutics, Inc.Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful and breakthrough treatments to improve the quality of life of patients. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to preclinical and clinical testing. Using a patient-centric approach, we collaborate and partner with a team of scientists, clinicians and key opinion leaders to research and study drugs that have immense potential to create breakthroughs and diversify treatment options. . To learn more, please visit

Investor contacts:LR Advisors LLCEmail: [email protected]www.hoththerapeutics.comPhone: (678) 570-6791

Quote Show original content to download multimedia: with-atopic-dermatitis-301572270.html

SOURCEHoth Therapeutics, Inc.


Comments are closed.